Bhagirath Divya, Zhao Xiangshan, West William W, Qiu Fang, Band Hamid, Band Vimla
Department of Genetics, Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Departments of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Oncotarget. 2015 Apr 20;6(11):9018-30. doi: 10.18632/oncotarget.3379.
Breast cancer is classified into different subtypes that are associated with different patient survival outcomes, underscoring the importance of understanding the role of precursor cell and genetic alterations in determining tumor subtypes. In this study, we evaluated the oncogenic phenotype of two distinct mammary stem/progenitor cell types designated as K5+/K19- or K5+/K19+ upon introduction of identical combinations of oncogenes-mutant H-Ras (mRas) and mutant p53 (mp53), together with either wild-type ErbB2(wtErbB2) or wild-type EGFR (wtEGFR). We examined their tumor forming and metastasis potential, using both in-vitro and in-vivo assays. Both the combinations efficiently transformed K5+/K19- or K5+/K19+ cells. Xenograft tumors formed by these cells were histologically heterogeneous, with variable proportions of luminal, basal-like and claudin-low type components depending on the cell types and oncogene combinations. Notably, K5+/K19- cells transformed with mRas/mp53/wtEGFR combination had a significantly longer latency for primary tumor development than other cell lines but more lung metastasis incidence than same cells expressing mRas/mp53/wtErbB2. K5+/K19+ cells exhibit shorter overall tumor latency, and high metastatic potential than K5+/K19- cells, suggesting that these K19+ progenitors are more susceptible to oncogenesis and metastasis. Our results suggest that both genetic alterations and cell type of origin contribute to oncogenic phenotype of breast tumors.
乳腺癌被分为不同的亚型,这些亚型与不同的患者生存结果相关,这突出了理解前体细胞和基因改变在确定肿瘤亚型中的作用的重要性。在本研究中,我们通过导入相同组合的致癌基因——突变型H-Ras(mRas)和突变型p53(mp53),以及野生型ErbB2(wtErbB2)或野生型EGFR(wtEGFR),评估了两种不同的乳腺干/祖细胞类型(分别命名为K5+/K19-或K5+/K19+)的致癌表型。我们使用体外和体内试验检测了它们的肿瘤形成和转移潜能。这两种组合都能有效地转化K5+/K19-或K5+/K19+细胞。这些细胞形成的异种移植肿瘤在组织学上是异质性的,根据细胞类型和致癌基因组合的不同,管腔型、基底样型和claudin低表达型成分的比例各不相同。值得注意的是,用mRas/mp53/wtEGFR组合转化的K5+/K19-细胞形成原发性肿瘤的潜伏期明显长于其他细胞系,但肺转移发生率高于表达mRas/mp53/wtErbB2的相同细胞。K5+/K19+细胞的总体肿瘤潜伏期比K5+/K19-细胞短,且转移潜能高,这表明这些K19+祖细胞更容易发生肿瘤发生和转移。我们的结果表明,基因改变和起源细胞类型都对乳腺肿瘤的致癌表型有影响。